ACEIs and ARBs may reduce incidence of atrial fibrillation by their anti-inflammatory characteristics.
Liu
Tong
T
Li
Guang-Ping
GP
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use*; D001281:Atrial Fibrillation / Q000378:metabolism / Q000517:prevention & control*; D002097:C-Reactive Protein / Q000378:metabolism; D006801:Humans
D057911:Angiotensin Receptor Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D000893:Anti-Inflammatory Agents; D002097:C-Reactive Protein